| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss and comprehensive loss | |||||||||
-51,255 | -3,475 | 321 | -7,433 | -19,023 | -21,786 | -16,938 | -31,771 | -18,117 | -29,508 |
Net income (loss) from discontinued operations | |||||||||
- | - | 12,070 | 226 | - | - | - | - | - | - |
Gain (loss) from discontinued operations | |||||||||
- | - | - | - | - | 691 | -1,068 | -6,095 | 108 | - |
Net loss from continuing operations | |||||||||
- | - | -11,749 | -7,659 | - | -22,477 | -15,870 | -25,676 | -18,225 | -29,508 |
Adjustments to reconcile net loss to net cash used in operating activities | |||||||||
Depreciation and amortization | |||||||||
- | - | 117 | 106 | 300 | 170 | 77 | 203 | 602 | 989 |
Non-cash interest, amortization of beneficial conversion feature and deferred financing costs | |||||||||
- | - | - | - | - | - | - | - | - | 8,728 |
Stock-based compensation expense | |||||||||
459 | 33 | 1,138 | 1,747 | 1,210 | 1,731 | 1,992 | 2,917 | 2,135 | 2,340 |
Research and development expensed - license acquired | |||||||||
3,000 | 0 | - | - | - | - | - | - | - | - |
Change in fair value of convertible notes payable | |||||||||
109 | 160 | - | - | - | - | - | - | - | - |
Change in fair value of warrant liabilities | |||||||||
16,501 | 0 | 646 | -7,479 | -3,236 | 0 | 0 | - | - | - |
Loss on disposal of fixed assets | |||||||||
- | - | - | - | -102 | 0 | 0 | - | - | - |
Loss on warrant issuance | |||||||||
5,020 | 0 | 0 | 461 | 0 | - | - | - | - | - |
Shares issued in connection with the fispemifene in-license agreement | |||||||||
- | - | - | - | - | -5,904 | 0 | 0 | - | - |
Deconsolidation of former French Subsidiaries | |||||||||
- | - | - | - | - | 846 | 641 | 0 | 0 | - |
Gain on contract settlement | |||||||||
- | - | - | - | - | 900 | 534 | 0 | 0 | - |
Recovery on loss on sale of subsidiary | |||||||||
- | - | - | - | - | 50 | 255 | 250 | -2,760 | - |
Derivative liability revaluation | |||||||||
- | - | - | - | - | -517 | 274 | 0 | 0 | - |
Loss on debt extinguishment | |||||||||
- | - | -422 | 0 | - | -51 | 0 | 0 | - | - |
Other | |||||||||
- | - | 2 | - | - | - | - | - | - | 205 |
Non-cash interest expense | |||||||||
- | - | 56 | 362 | 267 | 163 | 250 | 37 | 37 | - |
Interest on contingent consideration | |||||||||
- | - | - | - | - | 0 | 242 | 0 | 0 | - |
Non-cash deferred compensation | |||||||||
- | - | - | - | - | - | - | 640 | 0 | - |
Impairment charges on property held for sale | |||||||||
- | - | - | - | - | - | - | 656 | 0 | - |
Impairment charges on goodwill and intangible assets | |||||||||
- | - | - | - | - | - | - | 8,254 | 0 | 10,168 |
Deferred tax provision | |||||||||
- | - | - | - | - | - | - | 1,261 | 0 | - |
Other | |||||||||
- | - | - | -10 | -50 | 0 | -131 | 0 | -276 | - |
Changes in operating assets and liabilities from continuing operations: | |||||||||
Accounts receivable | |||||||||
- | - | - | - | -159 | 620 | -253 | -682 | -90 | -420 |
Inventories | |||||||||
- | - | - | - | 194 | -61 | 341 | 0 | -3 | - |
Decrease (increase) in other receivable | |||||||||
- | - | - | - | - | - | - | - | - | -188 |
Prepaid expenses and other current assets | |||||||||
686 | 6 | 84 | -408 | 466 | 464 | -143 | 928 | 54 | 237 |
Other assets | |||||||||
- | - | -25 | -40 | 13 | -2 | 52 | - | - | - |
Other assets | |||||||||
- | - | - | - | - | - | - | 0 | 17 | - |
Accounts payable | |||||||||
-1,424 | 1,672 | -705 | 45 | 609 | -66 | -920 | 681 | 989 | -639 |
Deconsolidation of Former French Subsidiaries | |||||||||
- | - | - | - | - | -2,000 | 0 | 0 | - | - |
Accrued expenses | |||||||||
1,533 | -96 | -681 | -1,340 | -1,276 | 2,465 | -476 | -1,348 | 1,228 | 537 |
Accrued interest | |||||||||
13 | 131 | - | - | - | - | - | - | - | - |
Current portion of licenses payable | |||||||||
7,100 | 0 | - | - | - | - | - | - | - | - |
Licenses payable, long-term | |||||||||
325 | 0 | - | - | - | - | - | - | - | - |
Accrued compensation | |||||||||
- | - | 249 | -360 | 111 | 160 | -140 | 967 | 86 | - |
Increase (decrease) in due to related party | |||||||||
- | - | - | - | - | - | - | - | - | -100 |
Deferred compensation | |||||||||
- | - | - | - | - | - | - | - | - | -61 |
Deferred revenue | |||||||||
- | - | - | - | -1,088 | -574 | 1,021 | -490 | 124 | 81 |
Deferred compensation | |||||||||
- | - | - | - | - | - | - | - | 134 | - |
Deferred revenue | |||||||||
- | - | 0 | - | - | - | - | - | - | - |
Other liabilities | |||||||||
- | - | -7 | -121 | -154 | -214 | -257 | -3 | 0 | - |
Net cash used in operating activities | |||||||||
-19,305 | -1,581 | -10,571 | -13,780 | - | -18,031 | -15,103 | -12,397 | -9,832 | -6,889 |
Net cash used in operating activities | |||||||||
- | - | - | - | -22,642 | - | - | - | - | - |
Purchase of fixed assets, net | |||||||||
- | - | - | 18 | 337 | 580 | 573 | 436 | 263 | 436 |
Proceeds from sale of subsidiary | |||||||||
- | - | - | - | - | 50 | 255 | 250 | 500 | - |
Proceeds from the sale of property and equipment | |||||||||
- | - | - | 3 | 5 | 0 | 3,657 | 0 | 0 | - |
Payment under convertible notes | |||||||||
- | - | - | - | - | 2,750 | 0 | 4,000 | 0 | - |
Release of restricted cash | |||||||||
- | - | - | 280 | 10 | 42 | 0 | 0 | - | - |
Deposit of restricted cash | |||||||||
- | - | - | - | - | 0 | 280 | - | - | - |
Cash acquired from acquisitions | |||||||||
- | - | - | - | - | - | - | 2,067 | 107 | - |
Cash paid for acquisitions | |||||||||
- | - | - | - | - | - | - | 513 | 0 | - |
Net cash provided by investing activities from continuing operations | |||||||||
- | - | - | 265 | - | -530 | 3,059 | 1,368 | 344 | -436 |
Net cash provided by (used in) investing activities | |||||||||
- | - | - | - | -322 | - | - | - | - | - |
Cash flows from financing activities: | |||||||||
Proceeds from issuance of common stock and warrants in a private offering | |||||||||
5,920 | 0 | - | - | - | - | - | - | - | - |
Proceeds from issuance of common stock in at-the-market offering | |||||||||
2,567 | 0 | - | - | - | - | - | - | - | - |
Issuance costs related to common stock and warrants | |||||||||
- | - | 1,392 | 641 | - | - | - | - | - | - |
Proceeds from issuance of common stock, pursuant to Securities Purchase Agreement, net of issuance costs | |||||||||
16,520 | 0 | 10,733 | 14,762 | 10,869 | 5,913 | 16,612 | 20,410 | 6,157 | 11,638 |
Proceeds from exercise of warrants | |||||||||
4,517 | 0 | 289 | 0 | - | 0 | 46 | 40 | 1,364 | 967 |
Proceeds from issuance of notes payable | |||||||||
- | - | - | - | 5,000 | 4,729 | 0 | 0 | - | - |
Repayment of notes payable | |||||||||
- | - | 7,129 | 3,113 | 495 | 0 | 0 | - | - | 2,592 |
Proceeds from convertible notes | |||||||||
0 | 1,365 | - | - | - | - | - | 3,413 | 0 | 6,187 |
Changes in derivative liability | |||||||||
- | - | - | - | - | - | - | 906 | 0 | - |
Proceeds from the exercise of stock options | |||||||||
- | - | - | - | 83 | 0 | 0 | 10 | 13 | - |
Net cash provided by financing activities | |||||||||
29,524 | 1,365 | 2,501 | - | 15,451 | - | - | - | - | - |
Release (deposit) of restricted cash | |||||||||
- | - | - | - | - | - | - | 0 | 0 | - |
Repayment of capital lease obligations | |||||||||
- | - | - | 5 | 6 | 27 | 27 | 13 | 20 | 6 |
Repayment of principal on note payable | |||||||||
- | - | - | - | - | - | - | - | -401 | 401 |
Deposit of restricted cash | |||||||||
- | - | - | - | - | - | - | - | 553 | -604 |
Retirement of restricted stock | |||||||||
- | - | - | - | - | 42 | 0 | 0 | - | - |
Net cash provided by financing activities from continuing operations | |||||||||
- | - | - | 11,003 | - | 7,865 | 16,631 | 20,766 | 7,666 | 15,991 |
Cash flows from discontinued operations: | |||||||||
Net cash (used in) provided by operating activities of discontinued operations | |||||||||
- | - | 105 | 712 | - | 16 | 38 | -1,985 | 111 | - |
Net cash provided by investing activities of discontinued operations | |||||||||
- | - | 12,209 | 0 | - | 675 | 1,650 | -300 | 0 | - |
Net cash provided by (used in) discontinued operations | |||||||||
- | - | 12,314 | 712 | - | 691 | 1,688 | -2,285 | 111 | - |
Effect of exchange rate changes on cash | |||||||||
- | - | - | - | - | - | - | 243 | 0 | - |
Net increase in cash | |||||||||
10,219 | -216 | 4,244 | -1,800 | -7,513 | -10,005 | 6,275 | 7,695 | -1,711 | 8,666 |
Supplemental disclosure of cash flow information: | |||||||||
Cash paid for interest | |||||||||
- | - | - | 646 | 538 | 193 | 238 | 318 | 333 | 228 |
Cash paid for income taxes | |||||||||
- | - | - | 6 | 5 | - | - | - | - | - |
Cash paid for interest | |||||||||
16 | 0 | 92 | - | - | - | - | - | - | - |
Cash paid for income taxes | |||||||||
0 | 0 | 0 | - | - | - | - | - | - | - |
Non-cash investing and financing activities: | |||||||||
Issuance of common stock for conversion of debt | |||||||||
2,551 | 0 | - | - | - | - | - | - | - | - |
Issuance of common stock for conversion of accrued interest | |||||||||
164 | 0 | - | - | - | - | - | - | - | - |
Issuance of common stock for license acquired | |||||||||
3,000 | 0 | - | - | - | - | - | - | - | - |
Effect of reverse merger | |||||||||
299 | 0 | - | - | - | - | - | - | - | - |
Reclass of warrant liabilities related to Series A warrants exercised for cash | |||||||||
5,600 | 0 | - | - | - | - | - | - | - | - |
Reclass of Series B warrants from warrant liability to stockholders' equity | |||||||||
31,473 | 0 | - | - | - | - | - | - | - | - |
Deferred offering costs | |||||||||
0 | 140 | - | - | - | - | - | - | - | - |
Transaction costs for 2016 financing activities | |||||||||
- | - | - | - | - | 0 | 0 | - | - | - |
Purchase of fixed assets not yet paid | |||||||||
- | - | - | - | 173 | 7 | 0 | 0 | - | - |
Issuance of 486,923 shares of common stock upon conversion of convertible note | |||||||||
- | - | - | - | - | 0 | 1,737 | 0 | 0 | - |
Issuance of placement agent warrants | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Reclassification of warrant liabilities to equity | |||||||||
- | - | 798 | 0 | - | - | - | - | - | - |
Issuance of placement agent warrants | |||||||||
- | - | 287 | 103 | - | - | - | - | - | - |
Issuance of restricted stock | |||||||||
- | - | - | 249 | 0 | - | - | - | - | - |
Accrued transaction costs for financing activities | |||||||||
- | - | - | 236 | - | - | - | - | - | - |
Release of restricted cash | |||||||||
- | - | - | - | - | 0 | 337 | 0 | 0 | - |
Release of obligations related to short-term loans | |||||||||
- | - | - | - | - | 0 | 270 | 0 | 0 | - |
Receipt of intellectual property in payment of due from related party | |||||||||
- | - | - | - | - | - | - | - | - | 205 |
Payment of interest in common stock | |||||||||
- | - | - | - | - | - | - | - | - | 597 |